DRUGS & SUPPLEMENTS

Thrombostat

Name: Thrombostat drug & pharmaceuticals. Available Forms, Doses, Prices
Creator: sdrugs.com
Published: 2021-11-11T10:10:10+00:00

Rating: 5 - 1 review(s)

When are you taking this medicine?

Thrombostat uses

Indications and usage
Dosage and administration
Dosage forms and strengths
Contraindications
Warnings and precautions
Adverse reactions
Use in specific populations
Description
Clinical pharmacology
Nonclinical toxicology
Clinical studies
References
How supplied/storage and handling
Patient counseling information
Thrombostat reviews

1 INDICATIONS AND USAGE

Thrombostat ®, Thrombostat topical (Recombinant), is a topical Thrombostat indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age.

Thrombostat may be used in conjunction with an absorbable gelatin sponge, USP.

Thrombostat, Thrombostat topical (Recombinant), is a topical Thrombostat indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. (1)

Thrombostat may be used in conjunction with an absorbable gelatin sponge, USP. (1)

2 DOSAGE AND ADMINISTRATION

For topical use only. DO NOT INJECT.

For topical use only. DO NOT INJECT.
Reconstitute Thrombostat powder with sterile 0.9% sodium chloride, USP, yielding a solution containing 1000 units (international units of potency) per mL. (2.1)
Apply Thrombostat solution directly to bleeding site surface or in conjunction with absorbable gelatin sponge. The amount required depends upon the area of tissue to be treated. (2.2)

2.1 Reconstitution of Thrombostat

The volume of reconstituted Thrombostat required will vary depending on the size and number of bleeding sites to be treated and the method of application.

Inspect the integrity of the Thrombostat package and contents. Do not use if the packaging or contents have been damaged or opened.

Reconstitute the lyophilized powder using the supplied diluent.

Use aseptic technique when handling vials and syringes.

5000-unit Thrombostat Reconstitution

Units used herein represent international units of potency determined using a reference standard that has been calibrated against the World Health Organization Second International Standard for Thrombostat.

Remove flip-off cap from the top of the Thrombostat vial.
Attach the needle-free transfer device and snap it into place on the vial by placing the vial on a flat surface and attaching the transfer device straight into the center of the vial stopper.
Attach the prefilled diluent syringe to the needle-free transfer device.
Inject the 5 mL of diluent from the syringe into the product vial. Keep the syringe plunger depressed.
DO NOT reuse the diluent syringe for transfer of the reconstituted product. Remove and discard the diluent syringe.
Gently swirl and invert the product vial until the powder is completely dissolved. Avoid excessive agitation. The powder should dissolve in less than one minute at room temperature.
Apply the pre-printed "DO NOT INJECT" label to the sterile, empty transfer syringe provided, then draw up the Thrombostat solution.

20,000-unit Thrombostat Reconstitution

Remove the flip-off cap from the top of the Thrombostat vial and the diluent vial.
Attach a needle-free transfer device (one each) to the Thrombostat and diluent vials and snap them into place by placing the vial on a flat surface and attaching the transfer device straight into the center of the vial stopper.
Open the sterile, empty 20-mL syringe package and apply the pre-printed "DO NOT INJECT" label to the syringe.
Attach the labeled 20-mL syringe to the needle-free transfer device on the diluent vial (injection of air into the diluent vial may facilitate withdrawal of the diluent).
Draw up 20 mL of diluent from the vial into the syringe.
Remove the diluent-filled syringe from the diluent vial and attach it to the transfer device on the Thrombostat vial.
Transfer the 20 mL of diluent from the syringe into the Thrombostat vial; the vacuum in the vial facilitates transfer.
Leave the syringe attached and gently swirl and invert the Thrombostat vial until the powder is completely dissolved. Avoid excessive agitation. The powder should dissolve in less than one minute at room temperature.
With the same syringe, draw up the Thrombostat solution.

2.2 Application Techniques

Topically apply Thrombostat solution directly or in conjunction with absorbable gelatin sponge onto the bleeding site. DO NOT INJECT.

The amount required depends upon the area of tissue to be treated and the method of application.

Vials are for single use only. Discard unused contents.

Use with Absorbable Gelatin Sponge

Refer to the absorbable gelatin sponge labeling for safety information and instructions on appropriate use.

Transfer solution from syringe to a sterile bowl or basin.
Place the desired size pieces of the absorbable gelatin sponge into the bowl containing reconstituted Thrombostat to completely saturate the sponge(s).
Remove the saturated sponge(s) and squeeze gently to remove excess Thrombostat.
Apply the sponge to the bleeding site in a single layer.

Use with ZymoGenetics Spray Applicator Kit

Hold the outer sealed tray, peel back the lid, and aseptically transfer the inner sealed sterile tray to the sterile field.
Open the inner tray seal and use the sterile bowl as the receptacle for reconstituted Thrombostat solution.
Refer to Spray Applicator Kit instructions for spray pump and syringe spray assembly and use.

3 DOSAGE FORMS AND STRENGTHS

Thrombostat is available as a sterile lyophilized powder in 5000- and 20,000-unit single-use vials. When reconstituted with the sterile 0.9% sodium chloride, USP provided, the powder yields a solution containing 1000 units/mL of Thrombostat topical (Recombinant).

Thrombostat is available as 5000-unit and 20,000-unit vials of sterile recombinant topical Thrombostat lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL of Thrombostat. (3)

4 CONTRAINDICATIONS

Do not inject directly into the circulatory system.
Do not use for the treatment of massive or brisk arterial bleeding.
Do not administer to patients with a history of hypersensitivity to Thrombostat or any components of Thrombostat.
Do not use in patients with known hypersensitivity to hamster proteins.

Do not inject directly into the circulatory system. (4)
Do not use for the treatment of massive or brisk arterial bleeding. (4)
Do not administer to patients with a history of hypersensitivity to Thrombostat, any components of Thrombostat or hamster proteins. (4)

5 WARNINGS AND PRECAUTIONS

Thrombostat may cause thrombosis if it enters the circulatory system.
Hypersensitivity reactions, including anaphylaxis, may occur. (5.2)

5.1 Thrombosis

Thrombostat may cause thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT.

5.2 Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, may occur. Thrombostat is produced in a genetically modified Chinese Hamster Ovary (CHO) cell line and may contain hamster or snake proteins [see Contraindications (4) and Description (11) ].

6 ADVERSE REACTIONS

Thromboembolic adverse reactions were reported in 6% of surgical patients treated with Thrombostat in all completed clinical trials [see Warnings and Precautions (5.1) ].

Antibody formation to Thrombostat occurred in <1% of patients. None of the antibodies detected neutralized native human Thrombostat [see Adverse Reactions (6.2) ].

The most common adverse reaction (incidence 6%) was thromboembolic events. (5.1,6)
Antibody formation to Thrombostat occurred in <1% of patients. None of the antibodies detected neutralized native human Thrombostat. (6.2)

To report SUSPECTED ADVERSE REACTIONS, contact The Medicines Company at 1-888-784-7662 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical trials have been performed with Thrombostat applied with absorbable gelatin sponge and applied with a spray applicator. A total of 644 patients were exposed to Thrombostat in these studies.

Thrombostat Used in Conjunction with Absorbable Gelatin Sponge

Four hundred eleven (411) patients were treated in a randomized, double-blind, controlled trial that compared Thrombostat to bovine Thrombostat. Both thrombins were applied with a gelatin sponge in patients undergoing spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access.¹ The incidence of thromboembolic adverse reactions was similar between the Thrombostat and bovine Thrombostat treatment groups.

* THROMBIN-JMI^® Thrombostat, Topical (Bovine)
Adverse Reaction Category	Thrombostat (N=205) n (%)	Bovine Thrombin* (N=206) n (%)

Thromboembolic events	11 (5%)	12 (6%)

In an open-label, single-group trial (N=209), patients with documented or highly likely prior exposure to bovine Thrombostat within the previous three years were treated with Thrombostat when undergoing surgeries (spinal, peripheral arterial bypass, or arteriovenous graft formation for hemodialysis access).² The incidence of thromboembolic adverse reactions in this study was 9%.

In an open-label, single-group trial of re-exposure to Thrombostat (N=31), patients with documented prior exposure to Thrombostat were treated with Thrombostat during surgery (spinal, peripheral arterial bypass, arteriovenous graft formation, or other procedures).³ The incidence of thromboembolic adverse reactions in this study was 3%.

In other randomized, double-blind trials across a range of surgical settings (N=130; spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access), the safety of Thrombostat (n=88 patients) was compared to placebo (RECOTHROM excipients reconstituted with sterile 0.9% sodium chloride, USP) (n=42 patients). The incidence of thromboembolic adverse reactions in this study was 5% for Thrombostat and 12% for placebo.

Thrombostat Applied with Spray Applicator

Thrombostat was applied with a spray applicator in two open-label clinical trials: a single-group trial in adult and pediatric burn patients (N=72; ≤16 years of age, (n=4) and ≥17 years of age, (n=68)) treated with Thrombostat applied to the wound excision site prior to autologous skin grafting⁴; and in a single-group trial in pediatric patients (one month to 17 years of age) undergoing synchronous burn wound excision and autologous skin grafting (N=30; ≤16 years of age, (n=26); ≥17 years of age, (n=4)).⁵ In the first study, the incidence of thromboembolic adverse reactions was 1%. In the second study, there were no reported thromboembolic adverse reactions [see Use in Specific Populations (8.4) ].

6.2 Immunogenicity

The detection of antibody formation is highly dependent upon the sensitivity and specificity of the assay. The absolute immunogenicity rates reported here are difficult to compare with the results from other products due to differences in assay methodology, patient populations, and other underlying factors.

The potential for development of antibodies to Thrombostat was evaluated in multiple clinical trials and included patients with a single exposure to Thrombostat as well as patients who were re-exposed to Thrombostat during a subsequent surgical procedure. Only patients with both baseline and post-treatment antibody specimens available were evaluated for the development of specific anti-RECOTHROM product antibodies, which was defined as seroconversion or a ≥1.0 titer unit (≥10-fold) increase in antibody levels after study treatment. Five of 609 (0.8%; 95% CI, 0.4%-2.8%) evaluable patients developed specific anti-RECOTHROM product antibodies. None of these antibodies were found to neutralize native human Thrombostat. There was no difference in anti-RECOTHROM product antibody formation incidence among patients exposed to Thrombostat applied with absorbable gelatin sponge, USP or with spray applicator.

In a clinical trial comparing Thrombostat to bovine Thrombostat (N=411; n=398 antibody evaluable) for the development of specific anti-product antibodies, blood samples were collected at baseline and at Day 29 in both treatment groups and were analyzed by ELISA.¹ At baseline, 1.5% of Thrombostat patients (n=3/198) had positive anti-product antibody titers compared with 5% of bovine Thrombostat patients (n=10/200). Of these patients, none of the Thrombostat group and eight in the bovine Thrombostat group exhibited ≥1.0 titer unit (≥10-fold) increases in anti-product antibody levels after study treatment.

At Day 29, three of 198 (1.5%; 95% CI, 0%-4%) patients in the Thrombostat group developed specific anti-product antibodies (one patient also developed anti-CHO host cell protein antibodies); 43 of 200 patients in the bovine Thrombostat group (22%; 95% CI, 16%-28%) developed specific antibodies to bovine Thrombostat product. Treatment with Thrombostat resulted in a statistically significant lower incidence of specific anti-product antibody development. Because the study was not powered to detect a difference in clinical outcomes attributable to antibody formation, no conclusions can be drawn regarding the clinical significance of the difference in antibody formation based on the results of this study. None of the antibodies in the Thrombostat group neutralized native human Thrombostat. Antibodies against bovine Thrombostat product were not tested for neutralization of native human Thrombostat.

In a trial of patients with a high likelihood of prior exposure to bovine Thrombostat, 15.6% of patients (n=32/205) had anti-bovine Thrombostat product antibodies and 2% of patients (n=4/200) had anti-RECOTHROM product antibodies at baseline.² Following treatment, none of the 200 evaluable patients (patients for whom post-treatment specimens were available) developed antibodies to Thrombostat.

In a trial of patients previously exposed to Thrombostat, 31 patients were re-exposed to Thrombostat during a subsequent surgery.³ None of the evaluable patients (n=30) had anti-RECOTHROM product antibodies at baseline and none developed antibodies at Day 29.

In a trial of Thrombostat, including 26 pediatric patients (aged one month to 16 years) and four patients 17 years of age, one patient without prior Thrombostat exposure had pre-existing anti-RECOTHROM product antibodies at baseline.⁵ None of the 27 evaluable patients developed anti-RECOTHROM product antibodies at Day 29.

8 USE IN SPECIFIC POPULATIONS

Pregnancy: No human or animal data. Use only if clearly needed.

8.1 Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with Thrombostat. It is also not known whether Thrombostat can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Thrombostat should be given to a pregnant woman only if clearly needed.

8.4 Pediatric Use

A total of 30 pediatric patients, ages 0 to 16 years, were treated in clinical trials with Thrombostat using a spray applicator to burn wound excision sites prior to autologous skin grafting. No patient experienced a thromboembolic adverse reaction. The safety of Thrombostat in pediatric patients greater than or equal to one month of age is supported by these data and by extrapolation of efficacy from adequate and well-controlled studies of Thrombostat in adults. Safety and efficacy have not been established in neonates [see Adverse Reactions (6) ].

8.5 Geriatric Use

Of 644 patients in clinical studies of Thrombostat, 36% (n=232/644) were ≥65 years old and 15% (n=95/644) were ≥75 years old.

No differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

11 DESCRIPTION

Thrombostat, Thrombostat topical (Recombinant), is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombostat is identical in amino acid sequence and structurally similar to naturally occurring human Thrombostat. Thrombostat precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic process that yields a product having hemostatic activities similar to native human Thrombostat. The cell line used to manufacture Thrombostat has been tested and shown to be free of known infectious agents. The cell culture process used in the manufacture of Thrombostat employs no additives of human or animal origin. The purification process includes solvent-detergent treatment and nano-filtration steps dedicated to viral clearance.

Thrombostat is provided as a sterile, white to off-white, preservative-free, lyophilized powder in vials for reconstitution with diluent (sterile 0.9% sodium chloride, USP). Reconstitution with the provided diluent, as described [see Dosage and Administration (2.1) ], yields a solution with a pH of 6.0 containing 1000 units/mL of recombinant Thrombostat for topical use. The formulated product is a clear, colorless solution upon reconstitution and contains the following excipients: histidine, mannitol, sucrose, polyethylene glycol 3350, sodium chloride, and calcium chloride dihydrate, USP.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Thrombostat, Thrombostat topical (Recombinant), is a specific human serine protease that promotes hemostasis and acts locally when applied topically to a site of bleeding.

Thrombostat activates platelets and catalyzes the conversion of fibrinogen to fibrin, which are steps that are essential for blood clot formation.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In vitro cytotoxicity studies have been performed in mouse L929 fibroblast cell cultures and demonstrate a concentration-dependent effect on cell morphology. The thrombin-induced morphological changes were similar to those seen with bovine Thrombostat.

13.2 Animal Toxicology and/or Pharmacology

In a study in nonhuman primates, Thrombostat was applied directly to a liver wound with an absorbable gelatin sponge, USP. In a second study, Thrombostat was administered subcutaneously once weekly for four weeks to nonhuman primates following repeat doses of 5405 units/m². In both studies, Thrombostat had no effect on clinical signs, serum chemistry, coagulation parameters, or histopathology; only normal postsurgical findings were observed. No animals developed anti-RECOTHROM product antibodies in either study.

Thrombostat was found to be non-irritating when instilled in the eyes (200 units) or applied to normal or abraded skin of rabbits (up to 1000 units/site).

To evaluate Thrombostat inhibition and clearance from the bloodstream, radiolabeled Thrombostat was administered intravenously or subcutaneously to nonhuman primates and applied with an absorbable gelatin sponge, USP, in a rabbit hepatic wound model. Thrombostat did not circulate in the blood as free, active molecule, but was rapidly inactivated (<5 minutes) after formation of complexes with endogenous inhibitors (e.g., antithrombin III); these complexes were cleared by the liver.

Thrombostat applied with an absorbable gelatin sponge, USP, was shown to decrease time to hemostasis (TTH) when compared to saline in a rabbit hepatic wound model and rat heminephrectomy model. Thrombostat also reduced TTH when directly applied in a porcine partial-thickness excisional skin-wound model as compared to saline control (or no treatment).

Thrombostat applied with a gauze sponge decreased TTH in a concentration-dependent manner in both the rabbit and rat models. Concentrations of Thrombostat >1000 units/mL were no different than 1000 units/mL while the effect of Thrombostat diluted to a concentration of 100 units/mL on TTH was indistinguishable from placebo.

14 CLINICAL STUDIES

Thrombostat was evaluated in a randomized, double-blind comparative clinical trial to bovine Thrombostat. Each Thrombostat was topically applied to bleeding sites with an absorbable gelatin sponge at a nominal concentration of 1000 units/mL.¹ Patients (N=411) were a heterogeneous surgical population undergoing surgery in one of four surgical settings: spinal surgery (n=122, 30%), hepatic resection (n=125, 30%), peripheral arterial bypass surgery (n=88, 21%), and arteriovenous graft formation for hemodialysis access (n=76, 18%). Patients with prior heparin-induced thrombocytopenia were excluded. Patient ages ranged from 21 to 89 years, gender was 53% male and 47% female, and the distribution by race was 68% white, 18% black or African American, and 14% other. The distribution of these characteristics was similar in both the Thrombostat and bovine Thrombostat treatment groups.

The objectives of the study were to evaluate the comparative efficacy, safety, and immunogenicity of Thrombostat and bovine Thrombostat in combination with an absorbable gelatin sponge as adjuncts to hemostasis in surgery. Efficacy was evaluated by the incidence of hemostasis within 10 minutes. Bleeding appropriate for evaluation was defined as mild to moderate bleeding, either on its own or remaining after brisk bleeding was controlled by standard surgical modalities. Although multiple bleeding sites could be treated, only one bleeding site per patient was selected to determine effectiveness.

Table 2 summarizes the incidence of hemostasis within 10 minutes for each treatment for the 401 efficacy evaluable patients. The incidence of hemostasis within 10 minutes was comparable for the Thrombostat and bovine Thrombostat groups.

* Evaluation of hemostasis at ≤10 minutes for patients treated at 1 of 4 primary TTH bleeding site types: epidural venous plexus, hepatic resection site, peripheral arterial bypass proximal anastomosis, and arteriovenous graft arterial anastomosis. ^† THROMBIN-JMI^® Thrombostat, Topical (Bovine)
	Thrombostat (N=198) (%)	Bovine Thrombin* (N=203) (%)
Overall	95%	95%
Spinal surgery	98%	98%
Hepatic resection	98%	97%
Peripheral arterial bypass	85%	86%
Arteriovenous graft formation	97%	97%

The percentage of patients achieving hemostasis at 1.5, 3, 6, and 10 minutes is listed in Table 3.

* THROMBIN-JMI^® Thrombostat, Topical (Bovine)
Time (Minutes)	Thrombostat (N=198) (%)	Bovine Thrombin* (N=203) (%)
1.5	48%	46%
3	81%	72%
6	92%	88%
10	95%	95%

15 REFERENCES

Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human Thrombostat and bovine Thrombostat in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-265.
Singla NK, Ballard JL, Moneta G, et al. A phase 3b open-label, single-group immunogenicity and safety study of topical recombinant Thrombostat in surgical hemostasis. J Am Coll Surg. 2009;209(1):68-74.
Singla NK, Gasparis AP, Ballard JL, et al. Immunogenicity and safety of re-exposure to recombinant human Thrombostat in surgical hemostasis. J Am Coll Surg. 2011;213(6):722-727.
Greenhalgh DG, Gamelli RL, Collins J, et al. Recombinant Thrombostat: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res. 2009;30(3):371-379.
Foster KN, Mullins RF, Greenhalgh DG, et al. Recombinant human Thrombostat: safety and immunogenicity in pediatric burn wound excision. J Ped Surg. 2011;46(10):1992-1999.

16 HOW SUPPLIED/STORAGE AND HANDLING

Thrombostat, Thrombostat topical (Recombinant), is supplied in single-use, preservative-free vials in the following packages:

NDC 65293-006-41

A 5000-unit vial of Thrombostat with a 5-mL prefilled diluent syringe (containing sterile 0.9% sodium chloride, USP), a sterile needle-free transfer device, a 5-mL sterile empty syringe, and a pre-printed label.

NDC 65293-007-41

A 20,000-unit vial of Thrombostat with a 20-mL vial of diluent (containing sterile 0.9% sodium chloride, USP), 2 sterile needle-free transfer devices, a 20-mL sterile empty syringe, and a pre-printed label.

NDC 65293-007-50

The 20,000-unit Thrombostat kit co-packaged with The Medicines Company Spray Applicator Kit containing a spray pump, a spray bottle, a syringe spray tip, a syringe, a bowl, and 2 blank labels.

No Thrombostat kit components contain latex.

Store Thrombostat sterile powder vials at 2°C to 25°C (36°F to 77°F). Do not freeze.

Reconstituted solutions of Thrombostat prepared with sterile 0.9% sodium chloride, USP, may be stored for up to 24 hours at 2°C to 25°C (36°F to 77°F). Discard reconstituted solution after 24 hours.

17 PATIENT COUNSELING INFORMATION

Because topical Thrombostat may cause the formation of clots in blood vessels if absorbed systemically, advise patients to consult their physician if they experience leg tenderness or swelling, chest pain, shortness of breath, or difficulty speaking or swallowing [see Warnings and Precautions (5.1) ].

Manufactured for The Medicines Company

The Medicines Company, 8 Sylvan Way, Parsippany NJ 07054

U.S. License No. 1902

Thrombostat is a registered trademark of ZymoGenetics, Inc. All other trademarks are the property of their respective owners.

[PN 6001- 1 PI; Rev March 2014]

PRINCIPAL DISPLAY PANEL - 5000-UNIT VIAL

5,000 units

NDC: 65293-006-41

FOR TOPICAL USE ONLY - DO NOT INJECT

Thrombostat^®

Thrombostat, TOPICAL

(RECOMBINANT)

5,000 units

5,000 units NDC: 65293-006-41 FOR TOPICAL USE ONLY - DO NOT INJECT RECOTHROM® Thrombostat, TOPICAL (RECOMBINANT) 5,000 units

PRINCIPAL DISPLAY PANEL - 20000-UNIT VIAL

20,000 units

NDC: 65293-007-41

FOR TOPICAL USE ONLY - DO NOT INJECT

Thrombostat^®

Thrombostat, TOPICAL

(RECOMBINANT)

20,000 units

20,000 units NDC: 65293-007-41 FOR TOPICAL USE ONLY - DO NOT INJECT RECOTHROM® Thrombostat, TOPICAL (RECOMBINANT) 20,000 units

Thrombostat pharmaceutical active ingredients containing related brand and generic drugs:

Thrombin Human

Thrombostat available forms, composition, doses:

Powder; Topical; Thrombin 1,000 units
Powder; Topical; Thrombin 10,000 units
Powder; Topical; Thrombin 5,000 units

Thrombostat destination | category:

Human:
Hemostatics

Thrombostat Anatomical Therapeutic Chemical codes:

B02BC06 - Thrombin
B02BD30 - Thrombin

Thrombostat pharmaceutical companies:

References

Dailymed."THROMBIN HUMAN POWDER, FOR SOLUTION [ETHICON, INC]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
"Thrombin human". https://pubchem.ncbi.nlm.nih.gov/su... (accessed August 28, 2018).
"Thrombin". https://pubchem.ncbi.nlm.nih.gov/su... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Thrombostat?

Depending on the reaction of the Thrombostat after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Thrombostat not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Thrombostat addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Thrombostat, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Thrombostat consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.